Skip to main content
    M

    Mainz Biomed BV (MYNZ)

    Official site

    DIAGNOSTICS & RESEARCH

    $0.63
    +0.07 (+12.15%)

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Mainz Biomed BV (MYNZ) Financials: Revenue, Profit and Cash Flow

    Updated Sep 3, 2025. Financial statements from company filings, amounts in US dollars.

    Mainz Biomed BV reported revenue of $893.99K for the fiscal year ended Dec 31, 2024, down 0.2% from the year before. That year, net income was -$21.65M with a net margin of -2421.8%, operating cash flow was -$17.09M and free cash flow was -$17.34M. The quarter ended Jun 30, 2025 had revenue of $286.72K and net income of -$8.34M.

    Revenue and Margins

    Over the 5 years to Dec 2024, revenue grew from $281.39K, a compound annual rate of 26.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$893.99K-0.2%64.3%-2091.2%-2421.8%
    Dec 2023$895.48K+69.0%56.9%-2975.5%-2936.5%
    Dec 2022$529.88K-8.2%34.4%-4990.6%-4992.2%
    Dec 2021$577.35K+17.0%30.8%-1684.4%-2024.8%
    Dec 2020$493.56K+75.4%24.9%-155.2%-118.9%
    Dec 2019$281.39KN/A-21.8%-327.6%-340.1%
    Annual, fiscal years ended Dec 2019 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss narrowed from the year before.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$893.99K$895.48K$529.88K$577.35K$493.56K$281.39K
    Cost of revenue$319.11K$385.82K$347.73K$399.73K$370.48K$342.66K
    Gross profit$574.88K$509.66K$182.15K$177.62K$123.08K-$61.27K
    Research and development$5.84M$9.59M$3.66M$466.69K$311.85K$250.32K
    Operating income-$18.70M-$26.64M-$26.44M-$9.72M-$766.09K-$921.91K
    Net income-$21.65M-$26.30M-$26.45M-$11.69M-$586.89K-$957.05K
    EBITDAN/A-$25.01M-$25.72MN/A-$257.64K-$702.08K
    Fiscal years ended Dec 2019 to Dec 2024

    Quarterly

    Line itemJun 2025Dec 2024Sep 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Revenue$286.72K$373.22K$520.77K$214.76K$214.76K$181.67K$500.21K$251.40K$144.34K$96.79K$278.48K$160.04K
    Gross profit-$310.34K$255.84K$319.04K$40.25K$134.73K$87.19K$277.88K$33.41KN/A$18.61K$148.74K-$174.92K
    Operating income-$8.09M-$8.89M-$9.81M-$12.23M-$6.80M-$5.64M-$12.98M-$12.28MN/A-$5.48M-$13.90M-$9.47M
    Net income-$8.34M-$10.63M-$11.02M-$5.18M-$5.18M-$6.30M-$13.27M-$12.58MN/A-$5.60M-$13.88M-$11.43M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents exceeded short-term debt of $2.41M by $3.83M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$13.24M$15.41M$20.24M$10.04M$673.27K$715.96K
    Current assets$7.84M$8.98M$18.38M$9.61M$186.40K$260.01K
    Cash and equivalents$6.24M$7.07M$17.14M$8.73M$122.57K$203.59K
    Total liabilities$7.19M$12.16M$6.14M$3.68M$3.41M$2.67M
    Short-term debt$2.41M$5.22M$1.33M$248.51K$266.63K$207.26K
    Long-term debtN/A$1.03M$943.21K$1.94M$447.18K$369.48K
    Shareholder equity$6.05M$3.25M$14.10M$6.36M-$2.74M-$1.95M
    Fiscal years ended Dec 2019 to Dec 2024

    Quarterly

    Line itemJun 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022
    Total assets$9.80M$13.24M$8.45M$8.45M$15.41M$15.41M$17.91M$19.31M$20.24M$20.24MN/A$27.62M
    Total liabilities$7.28M$7.19M$12.59M$12.59M$12.16M$12.16M$14.46M$14.13M$6.14M$6.14MN/A$3.84M
    Cash and equivalents$1.91M$6.24M$977.76K$977.76K$7.07M$7.07M$9.32M$10.91M$17.14M$17.14MN/A$26.01M
    Shareholder equity$2.52M$6.05M-$4.14M-$4.14M$3.25M$3.25M$3.45M$5.18M$14.10M$14.10MN/A$23.77M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$17.09M-$21.94M-$14.77M-$3.22M-$468.74K-$416.50K
    Capital expenditures$254.95K$1.90M$658.48K$16.70K$9.69K$9.69K
    Free cash flow-$17.34M-$23.84M-$15.43M-$3.24M-$478.42K-$426.18K
    Investing cash flow-$198.82K-$1.90M-$658.48K$1.20M-$9.69K-$9.69K
    Financing cash flow$16.60M$14.23M$23.94M$10.61M$396.68K$424.00K
    Fiscal years ended Dec 2019 to Dec 2024

    Quarterly

    Line itemJun 2025Dec 2024Sep 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$6.52M-$8.95M-$8.14M-$4.66M-$4.66M-$6.51M-$5.12M-$8.31M-$805.08K
    Capital expenditures$1.12K$134.29K$120.66K$261.81K$261.81K$112.48K$123.63K$406.04KN/A
    Free cash flow-$6.52M-$9.08M-$8.27M-$4.92M-$4.92M-$6.62M-$5.24M-$8.72MN/A
    Last 9 quarters

    Frequently Asked Questions About MYNZ

    What is Mainz Biomed BV's annual revenue?

    Mainz Biomed BV reported revenue of $893.99K for the fiscal year ended Dec 31, 2024.

    How fast is Mainz Biomed BV's revenue growing?

    Revenue was down 0.2% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was 15.7%.

    Is Mainz Biomed BV profitable?

    No. Mainz Biomed BV reported net income of -$21.65M for the fiscal year ended Dec 31, 2024, with a net margin of -2421.8%.

    How much free cash flow does MYNZ generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$17.09M minus capital expenditures of $254.95K produced free cash flow of -$17.34M.

    How much debt does Mainz Biomed BV have?

    The balance sheet dated Dec 31, 2024 reported short-term debt of $2.41M and cash and equivalents of $6.24M.